All Online

1 - 5 of 5 results

Refine

Active filters

Lipid Disorders (Dyslipidemia)
patient-centric-treatment-of-diabetes-the-role-of-glp-1-receptor-agonists

There are several challenges in the management of T2DM that faces clinicians today in the real-world setting. This case study is designed to improve clinician competence and practice.


There are several challenges in the management of T2DM that faces clinicians today in the real-world setting. This case study is designed to improve clinician competence and practice.


fit old man with relaxed facial expression

In this case presentation, P. Barton Duell, M.D., Director, Lipid Disorders Clinic and LDL Apheresis, and Director, Lipid-Atherosclerosis Laboratory at the Knight Cardiovascular Institute at Oregon Health and Science University, shares strategies for assessing cardiovascular risk and customizing lipid lowering therapy in an asymptomatic physically active 66 year-old man with mildly elevated LDL cholesterol and a strong family history of cardiovascular disease. Dr. Duell also discusses use of recently approved PCSK9 inhibitors for cholesterol reduction in patients with established cardiovascular disease.


Inhibitors of the PCSK9 protein represent an important new therapeutic class for patients with familiar hypercholesterolemia or established CVD who require further LDL-C lowering beyond what statins can provide. This Case Curriculum illustrates two patient scenarios for the use of PCSK9 inhibitors, and reviews selection of patients who require more intensive LDL-C lowering and clinical efficacy and safety data for these novel agents.